Zentalis Pharmaceuticals Inc (ZNTL) Stock Price, Quote & News

Company Profile

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers in the United States. It develops azenosertib, which is in a Phase 3 clinical trial for the treatment of ovarian cancer and other tumor types. The company also develops ZN-c3-001, a phase 1 study that evaluated azenosertib monotherapy in solid tumors; and MAMMOTH (ZN-c3-006) is a Phase 1/2 clinical trial of azenosertib...

Industry: Biotechnology

Sector: Healthcare

Phone: 858 263 4333

Website: zentalis.com

Address:

10275 Science Center Dr., Suite 200, San Diego, United States

lucabrix Jun. 7 at 8:21 PM

$ZNTL hope Snackdaddy sees under 3 again LOL!

0 · Reply

lucabrix Jun. 3 at 8:13 PM

$ZNTL waiting for some news to come

0 · Reply

zawojak Jun. 2 at 9:59 AM

$ZNTL dead forum, dead stock

0 · Reply

Sillyspuh May. 28 at 7:29 PM

$ZNTL Adding some commercialization talent to the bench: https://ir.zentalis.com/news--events/press-releases/press-releases-details/2026/Zentalis-Strengthens-Commercial-Leadership-with-Appointments-of-Shannon-Campbell-to-Board-of-Directors-and-Sarah-Kelly-as-SVP-of-Commercial-Strategy/default.aspx

0 · Reply

SuperGreenToday May. 26 at 9:06 PM

$ZNTL Share Price: $3.96 Contract Selected: Dec 18, 2026 $5 Calls Buy Zone: $1.23 – $1.52 Target Zone: $2.22 – $2.72 Potential Upside: 70% ROI Time to Expiration: 205 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

STACKD0E May. 23 at 3:45 AM

$ZNTL

1 · Reply

focafoca99 May. 22 at 12:12 AM

$ZNTL highlighted encouraging Phase 1b data on azenosertib plus paclitaxel at ASCO 2026.

0 · Reply

focafoca99 May. 21 at 9:38 PM

$ZNTL released Phase 1b trial data at ASCO, reporting a 39.1% overall response rate in ovarian cancer.

0 · Reply

Sillyspuh May. 21 at 8:10 PM

$ZNTL Could have been a little bit of a run before the Muir trial abstract is released for ASCO today.

0 · Reply

Snackdaddy May. 19 at 11:15 AM

$ZNTL bio has been getting bomed out. you may get this sub $3

3 · Reply

Zentalis Pharmaceuticals Transcript: Jefferies Global Healthcare Conference 2026

Jun 1, 2026, 5:00 PM EDT - 7 days ago

Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 27, 2026, 4:05 PM EDT - 12 days ago

Zentalis Strengthens Commercial Leadership with Appointments of Shannon Campbell to Board of Directors and Sarah Kelly as SVP of Commercial Strategy

May 27, 2026, 8:00 AM EDT - 12 days ago

Zentalis Pharmaceuticals Proxy statement: Proxy filing

May 26, 2026, 10:00 AM EDT - 13 days ago

Zentalis Pharmaceuticals Transcript: 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA

May 21, 2026, 5:39 PM EDT - 18 days ago

Zentalis Pharmaceuticals to Present Phase 1b MUIR Trial Data Showing Encouraging Clinical Activity and Manageable Safety Profile of Azenosertib Plus Paclitaxel in Platinum-Resistant Ovarian Cancer at ASCO 2026

May 20, 2026, 4:30 PM EDT - 19 days ago

Zentalis Pharmaceuticals Transcript: Stifel 2026 Targeted Oncology Virtual Forum

May 19, 2026, 2:30 PM EDT - 20 days ago

Zentalis Pharmaceuticals Transcript: H.C. Wainwright 4th Annual BioConnect Investor Conference

May 13, 2026, 4:05 PM EDT - 26 days ago

Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences

May 12, 2026, 4:05 PM EDT - 27 days ago

Zentalis Pharmaceuticals Reports First Quarter 2026 Financial Results and Clinical Progress

May 12, 2026, 7:00 AM EDT - 27 days ago

Zentalis Pharmaceuticals Quarterly report: Q1 2026

May 12, 2026, 7:00 AM EDT - 27 days ago

Zentalis Pharmaceuticals Earnings release: Q1 2026

May 12, 2026, 7:00 AM EDT - 27 days ago

Zentalis Pharmaceuticals Slides: Corporate presentation

May 5, 2026, 8:00 AM EDT - 4 weeks ago

Zentalis Pharmaceuticals Announces First Patient Dosed in ASPENOVA Phase 3 Trial of Azenosertib in Patients with Cyclin E1-Positive Platinum-Resistant Ovarian Cancer

May 1, 2026, 5:30 PM EDT - 5 weeks ago

Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Apr 30, 2026, 8:00 AM EDT - 5 weeks ago

Zentalis Pharmaceuticals Proxy statement: Proxy filing

Apr 30, 2026, 8:00 AM EDT - 5 weeks ago

Zentalis Pharmaceuticals Proxy statement: Proxy filing

Apr 21, 2026, 10:27 AM EDT - 6 weeks ago

Zentalis Pharmaceuticals Announces Abstract Acceptance at ASCO 2026 Featuring Azenosertib in Combination with Paclitaxel for Platinum-Resistant Ovarian Cancer

2026-04-17T19:20:16.000Z - 7 weeks ago

Zentalis to present azenosertib preclinical data in TNBC at AACR meeting

Apr 17, 2026, 3:15 PM EDT - 7 weeks ago

Zentalis Pharmaceuticals To Present Azenosertib Preclinical Data in Triple-Negative Breast Cancer and Real-World Analysis of Unmet Need in Cyclin E1-Positive Ovarian Cancer at AACR 2026

2026-04-10T11:01:05.000Z - 2 months ago

Zentalis price target raised to $10 from $6 at Guggenheim

Apr 9, 2026, 8:00 AM EDT - 2 months ago

Zentalis Pharmaceuticals Announces 400mg QD 5:2 Azenosertib Monotherapy as the Pivotal Study Dose in Cyclin E1-Positive Platinum-Resistant Ovarian Cancer

Apr 9, 2026, 7:00 AM EDT - 2 months ago

Zentalis Pharmaceuticals Slides: Corporate presentation

Mar 26, 2026, 4:05 PM EDT - 2 months ago

Zentalis Pharmaceuticals Reports Full Year 2025 Financial Results and Operational Updates

Mar 26, 2026, 4:00 PM EDT - 2 months ago

Zentalis Pharmaceuticals Annual report: Q4 2025

Mar 26, 2026, 4:00 PM EDT - 2 months ago

Zentalis Pharmaceuticals Earnings release: Q4 2025

Mar 17, 2026, 4:30 PM EDT - 2 months ago

Zentalis Pharmaceuticals to Present Two Posters at the American Association for Cancer Research (AACR) Annual Meeting 2026

Mar 9, 2026, 1:00 PM EDT - 3 months ago

Zentalis Pharmaceuticals Transcript: Leerink Global Healthcare Conference 2026

Mar 3, 2026, 10:30 AM EST - 3 months ago

Zentalis Pharmaceuticals Transcript: TD Cowen 46th Annual Health Care Conference

Feb 25, 2026, 12:40 PM EST - 3 months ago

Zentalis Pharmaceuticals Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference

Feb 11, 2026, 3:30 PM EST - 4 months ago

Zentalis Pharmaceuticals Transcript: Guggenheim Securities Emerging Outlook: Biotech Summit 2026

Feb 3, 2026, 4:05 PM EST - 4 months ago

Zentalis Pharmaceuticals to Participate in Upcoming Investor Conference

Jan 9, 2026, 6:00 AM EST - 5 months ago

Zentalis Pharmaceuticals Slides: Corporate presentation

2026-01-06T13:05:12.000Z - 5 months ago

Zentalis provides update, key milestones in 2025, expectations for 2026

Jan 6, 2026, 8:00 AM EST - 5 months ago

Zentalis Pharmaceuticals Provides Corporate Update and Highlights Key Milestones and Expected Momentum in the Azenosertib Development Program for 2026

Nov 12, 2025, 8:00 AM EST - 7 months ago

Zentalis Pharmaceuticals Transcript: Stifel 2025 Healthcare Conference

Nov 11, 2025, 3:30 PM EST - 7 months ago

Zentalis Pharmaceuticals Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference

2025-11-11T15:05:50.000Z - 7 months ago

Zentalis price target lowered to $4 from $8 at Morgan Stanley

Nov 10, 2025, 4:05 PM EST - 7 months ago

Zentalis Pharmaceuticals Reports Third Quarter 2025 Financial Results and Operational Progress

Nov 10, 2025, 7:00 AM EST - 7 months ago

Zentalis Pharmaceuticals Earnings release: Q3 2025

Nov 10, 2025, 7:00 AM EST - 7 months ago

Zentalis Pharmaceuticals Quarterly report: Q3 2025

Nov 9, 2025, 6:00 PM EST - 7 months ago

Zentalis Pharmaceuticals Slides: Corporate Presentation

Oct 13, 2025, 4:05 PM EDT - 8 months ago

Zentalis Pharmaceuticals Announces Four Azenosertib Posters Presentations at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

2025-09-24T19:40:20.000Z - 9 months ago

Zentalis board member Letai frontrunner to lead NCI, STAT reports

Sep 9, 2025, 7:00 AM EDT - 9 months ago

Zentalis Pharmaceuticals Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference

Sep 8, 2025, 2:30 PM EDT - 9 months ago

Zentalis Pharmaceuticals Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 4, 2025, 10:15 AM EDT - 9 months ago

Zentalis Pharmaceuticals Transcript: Wells Fargo 20th Annual Healthcare Conference 2025

2025-08-26T20:10:19.000Z - 10 months ago

Zentalis CLO Andrea Paul to depart, James Bucher to succeed

Aug 26, 2025, 4:05 PM EDT - 10 months ago

Zentalis Pharmaceuticals Appoints James B. Bucher, JD, as Chief Legal Officer and Corporate Secretary

2025-08-07T10:27:10.000Z - 10 months ago

Zentalis price target lowered to $5 from $6 at Wells Fargo

Aug 6, 2025, 4:05 PM EDT - 10 months ago

Zentalis Pharmaceuticals Reports Second Quarter 2025 Financial Results and Operational Progress

Aug 6, 2025, 7:00 AM EDT - 10 months ago

Zentalis Pharmaceuticals Earnings release: Q2 2025

Aug 6, 2025, 7:00 AM EDT - 10 months ago

Zentalis Pharmaceuticals Quarterly report: Q2 2025

Jun 4, 2025, 9:55 AM EDT - 1 year ago

Zentalis Pharmaceuticals Transcript: Jefferies Global Life Sciences Conference

Jun 4, 2025, 9:55 AM EDT - 1 year ago

Zentalis Pharmaceuticals Slides: Jefferies Global Life Sciences Conference

May 27, 2025, 11:00 AM EDT - 1 year ago

Zentalis Pharmaceuticals Transcript: TD Cowen's 6th Annual Oncology Innovation Summit

May 23, 2025, 8:00 AM EDT - 1 year ago

Zentalis Pharmaceuticals Proxy statement: Proxy Filing

May 20, 2025, 11:30 AM EDT - 1 year ago

Zentalis Pharmaceuticals Transcript: H.C. Wainwright 3rd Annual BioConnect Investor Conference 2025

2025-05-15T13:07:58.000Z - 1 year ago

Zentalis price target lowered to $9 from $10 at Oppenheimer

May 14, 2025, 4:05 PM EDT - 1 year ago

Zentalis Pharmaceuticals Reports First Quarter 2025 Financial Results and Operational Progress

May 14, 2025, 7:00 AM EDT - 1 year ago

Zentalis Pharmaceuticals Earnings release: Q1 2025

May 14, 2025, 7:00 AM EDT - 1 year ago

Zentalis Pharmaceuticals Quarterly report: Q1 2025

Apr 30, 2025, 8:00 AM EDT - 1 year ago

Zentalis Pharmaceuticals Proxy statement: Proxy Filing

Apr 30, 2025, 8:00 AM EDT - 1 year ago

Zentalis Pharmaceuticals Proxy statement: Proxy Filing

2025-04-28T12:11:44.000Z - 1 year ago

Zentalis announces first patient dosed in DENALI Part 2 trial of azenosertib

Apr 28, 2025, 8:00 AM EDT - 1 year ago

Zentalis Pharmaceuticals Announces First Patient Dosed in DENALI Part 2 Clinical Trial of Azenosertib in Patients with Cyclin E1+ PROC

Apr 23, 2025, 4:05 PM EDT - 1 year ago

Zentalis Pharmaceuticals Announces Poster Presentation at 2025 ASCO Annual Meeting

2025-03-26T20:25:24.000Z - 1 year ago

Zentalis files $250M mixed securities shelf

Mar 26, 2025, 4:05 PM EDT - 1 year ago

Zentalis Pharmaceuticals Reports Full Year 2024 Financial Results and Operational Updates

Mar 26, 2025, 11:30 AM EDT - 1 year ago

Zentalis Pharmaceuticals Earnings release: Q4 2024

Mar 26, 2025, 11:30 AM EDT - 1 year ago

Zentalis Pharmaceuticals Annual report: Q4 2024

Mar 26, 2025, 8:00 AM EDT - 1 year ago

Zentalis Pharmaceuticals Registration statement: Registration Filing

Mar 25, 2025, 4:40 PM EDT - 1 year ago

Zentalis Pharmaceuticals to Present Multiple Posters at the American Association for Cancer Research (AACR) Annual Meeting 2025

2025-03-16T22:40:38.000Z - 1 year ago

Zentalis presents updated clinical data on azenosertib as SGO 2025

Mar 15, 2025, 11:25 AM EDT - 1 year ago

Zentalis Pharmaceuticals Presents Updated Clinical Data at the Society of Gynecologic Oncology 2025 Annual Meeting on Women's Cancer

Mar 10, 2025, 9:20 AM EDT - 1 year ago

Zentalis Pharmaceuticals Transcript: Leerink Global Healthcare Conference 2025

Mar 10, 2025, 9:20 AM EDT - 1 year ago

Zentalis Pharmaceuticals Slides: FY 2025

Mar 3, 2025, 11:50 AM EST - 1 year ago

Zentalis Pharmaceuticals Transcript: TD Cowen 45th Annual Healthcare Conference

Mar 3, 2025, 11:50 AM EST - 1 year ago

Zentalis Pharmaceuticals Slides: TD Cowen 45th Annual Healthcare Conference

Mar 3, 2025, 8:00 AM EST - 1 year ago

Zentalis Pharmaceuticals Announces Multiple Data Presentations at Society of Gynecologic Oncology 2025 Annual Meeting on Women's Cancer

2025-01-30T13:21:32.000Z - 1 year ago

Zentalis price target lowered to $6 from $8 at Guggenheim

2025-01-30T12:42:35.000Z - 1 year ago

Zentalis price target lowered to $6 from $8 at Wells Fargo

2025-01-29T15:55:15.000Z - 1 year ago

Zentalis price target lowered to $10 from $20 at H.C. Wainwright

2025-01-29T15:20:22.000Z - 1 year ago

Zentalis price target lowered to $10 from $20 at Oppenheimer

Jan 29, 2025, 8:00 AM EST - 1 year ago

Zentalis Pharmaceuticals Transcript: Study Update

Jan 29, 2025, 8:00 AM EST - 1 year ago

Zentalis Pharmaceuticals Press release: Study Update

Jan 29, 2025, 8:00 AM EST - 1 year ago

Zentalis Pharmaceuticals Slides: Study Update

Jan 29, 2025, 7:00 AM EST - 1 year ago

Zentalis Pharmaceuticals Shares Updated Clinical Data Demonstrating Meaningful Azenosertib Activity in Cyclin E1+, Platinum-Resistant Ovarian Cancer

Jan 28, 2025, 4:05 PM EST - 1 year ago

Zentalis Pharmaceuticals Announces Strategic Restructuring to Support Late-Stage Azenosertib Development

Jan 9, 2025, 7:00 AM EST - 1 year ago

Zentalis Pharmaceuticals Announces Azenosertib Fast Track Designation and Virtual Corporate Event to Present Updated Data from Azenosertib Clinical Studies

Dec 12, 2024, 7:00 AM EST - 1 year ago

Zentalis Pharmaceuticals Announces Key Management Appointments

Nov 21, 2024, 1:14 PM EST - 1 year ago

Kuehn Law Encourages Investors of Zentalis Pharmaceuticals, Inc. to Contact Law Firm

Nov 12, 2024, 9:30 AM EST - 1 year ago

Zentalis Pharmaceuticals Quarterly report: Q3 2024

Oct 7, 2024, 2:03 PM EDT - 1 year ago

FMR LLC Adjusts Its Stake in Zentalis Pharmaceuticals Inc

Sep 16, 2024, 7:00 AM EDT - 1 year ago

Zentalis Pharmaceuticals Announces FDA Has Lifted Partial Clinical Hold on Azenosertib Studies

Sep 9, 2024, 7:00 AM EDT - 1 year ago

Zentalis Pharmaceuticals to Present Preclinical Azenosertib Data at ESMO 2024

Aug 19, 2024, 4:55 PM EDT - 1 year ago

Newman Ferrara LLP Announces Corporate Governance Investigation of Zentalis Pharmaceuticals, Inc. – ZNTL

lucabrix Jun. 7 at 8:21 PM

$ZNTL hope Snackdaddy sees under 3 again LOL!

0 · Reply

lucabrix Jun. 3 at 8:13 PM

$ZNTL waiting for some news to come

0 · Reply

zawojak Jun. 2 at 9:59 AM

$ZNTL dead forum, dead stock

0 · Reply

Sillyspuh May. 28 at 7:29 PM

0 · Reply

SuperGreenToday May. 26 at 9:06 PM

0 · Reply

STACKD0E May. 23 at 3:45 AM

$ZNTL

1 · Reply

focafoca99 May. 22 at 12:12 AM

$ZNTL highlighted encouraging Phase 1b data on azenosertib plus paclitaxel at ASCO 2026.

0 · Reply

focafoca99 May. 21 at 9:38 PM

$ZNTL released Phase 1b trial data at ASCO, reporting a 39.1% overall response rate in ovarian cancer.

0 · Reply

Sillyspuh May. 21 at 8:10 PM

$ZNTL Could have been a little bit of a run before the Muir trial abstract is released for ASCO today.

0 · Reply

Snackdaddy May. 19 at 11:15 AM

$ZNTL bio has been getting bomed out. you may get this sub $3

3 · Reply

DavynStox May. 18 at 4:16 PM

$ZNTL ASCO abstracts for Azenosertib phase 1b trial on Thursday! https://www.asco.org/abstracts-presentations/268104

0 · Reply

focafoca99 May. 13 at 8:24 PM

$ZNTL lists multiple upcoming investor conference appearances in May and June.

1 · Reply

Sillyspuh May. 13 at 12:07 AM

$ZNTL Q1 2026 financial report: https://ir.zentalis.com/news--events/press-releases/press-releases-details/2026/Zentalis-Pharmaceuticals-Reports-First-Quarter-2026-Financial-Results-and-Clinical-Progress/default.aspx

1 · Reply

AbovetheGreenLine May. 8 at 1:51 PM

$ZNTL is Don't Take a Loss! https://abovethegreenline.com/wp-content/uploads/2021/01/ST-1.jpg https://zpr.io/ALAFEXsBQr7Z

0 · Reply

Sillyspuh May. 5 at 5:49 PM

$ZNTL First dose given of phase 3 Aspenova confirmatory trial. A big accomplishment that should continue to derisk this stock. https://ir.zentalis.com/news-releases/news-release-details/zentalis-pharmaceuticals-announces-first-patient-dosed-aspenova

0 · Reply

Dark_Horse_Investments May. 4 at 11:18 PM

$ZNTL Taking a deeper dive into WEE1 gene inhibitor which blocks the G2/M checkpoint in certain ovarian cancers. From what I know/have learned, high grade serous ovarian cancer (HGSOC) significantly relies on WEE1 because they already live in a state of constant replication stress. Need to learn more of why this is. Yearly new ovarian cancer diagnosis in USA number 15k – 20k of which many will become platinum resistant. Current treatment is suboptimal, and none targets WEE1 (ie low ORR, ~4–13% & short DOR in PROC). I think there is something here… Any initial reactions about this pursuit? Stay longs & disciplined my friends!

1 · Reply

AbovetheGreenLine Apr. 27 at 7:10 PM

Swing Trade Buy on the Close for Zentalis Pharma. $ZNTL. https://abovethegreenline.com/wp-content/uploads/2021/01/ST-1.jpg https://zpr.io/z

0 · Reply

Snackdaddy Apr. 24 at 1:40 PM

$ZNTL wow. still dropping didnt see this going back to $2S but maybe

1 · Reply

Snackdaddy Apr. 22 at 6:03 PM

$ZNTL still getting beat up. can this actually retrace to $2S?

0 · Reply

Stef_Gee Apr. 22 at 11:29 AM

$ZNTL That was the original one ... 😉

1 · Reply

Stef_Gee Apr. 22 at 11:26 AM

$ZNTL 🫡

0 · Reply

Stef_Gee Apr. 22 at 11:22 AM

$ZNTL Again ... 😏

0 · Reply

Market Cap	260.54M
Revenue (ttm)	0.00
Net Income (ttm)	-137.06M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	507,400
Avg Vol	2,368,622
Day's Range	N/A - N/A
Shares Out	71.19M
Stochastic %K	23%
Beta	1.96
Analysts	Sell
Price Target	$6.50